Expression of CD133 and other putative stem cell markers in uveal melanoma.

Standard

Expression of CD133 and other putative stem cell markers in uveal melanoma. / Berna-Thill, Michelle; Berna, Marc; Grierson, Rebecca; Reinhart, Inna; Voelkel, Tobias; Piechaczek, Christoph; Galambos, Peter; Jager, Martine J; Richard, Gisbert; Lange, Claudia; Gehling, Ursula.

in: MELANOMA RES, Jahrgang 21, Nr. 5, 5, 2011, S. 405-416.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Berna-Thill, M, Berna, M, Grierson, R, Reinhart, I, Voelkel, T, Piechaczek, C, Galambos, P, Jager, MJ, Richard, G, Lange, C & Gehling, U 2011, 'Expression of CD133 and other putative stem cell markers in uveal melanoma.', MELANOMA RES, Jg. 21, Nr. 5, 5, S. 405-416. <http://www.ncbi.nlm.nih.gov/pubmed/21900792?dopt=Citation>

APA

Berna-Thill, M., Berna, M., Grierson, R., Reinhart, I., Voelkel, T., Piechaczek, C., Galambos, P., Jager, M. J., Richard, G., Lange, C., & Gehling, U. (2011). Expression of CD133 and other putative stem cell markers in uveal melanoma. MELANOMA RES, 21(5), 405-416. [5]. http://www.ncbi.nlm.nih.gov/pubmed/21900792?dopt=Citation

Vancouver

Berna-Thill M, Berna M, Grierson R, Reinhart I, Voelkel T, Piechaczek C et al. Expression of CD133 and other putative stem cell markers in uveal melanoma. MELANOMA RES. 2011;21(5):405-416. 5.

Bibtex

@article{bdcbf9b57a00492dba1eda7987ad2c4c,
title = "Expression of CD133 and other putative stem cell markers in uveal melanoma.",
abstract = "'Cancer stem cells' (CSCs) are tumor cells with stem cell properties hypothesized to be responsible for tumorigenesis, metastatis, and resistance to treatment, and have been identified in different tumors including cutaneous melanoma, using stem cell markers such as CD133. This study explored expression of CD133 and other putative stem cell markers in uveal melanoma. Eight uveal melanoma cell lines were subjected to flow-cytometric (fluorescence-activated cell sorting) analysis of CD133 and other stem cell markers. Eight paraffin-embedded tumors were analyzed by immunohistochemistry for CD133, Pax6, Musashi, nestin, Sox2, ABCB5, and CD68 expressions. Ocular, uveal melanoma, and hematopoietic stem cell distributions of C-terminal and N-terminal CD133 mRNA splice variants were compared by reverse-transcription PCR. Fluorescence-activated cell sorting analysis revealed a population of CD133-positive/nestin-positive cells in cell lines Mel270, OMM 2.3, and OMM2.5. All cell lines studied were positive for nestin, CXCR-4, CD44, and c-kit. Immunohistochemistry identified cells positive for CD133, Pax6, Musashi, nestin, Sox2, ABCB5, and CD68 predominantly at the invading tumor front. C-terminal primers interacting with CD133 splice variant s2 detected a novel variant lacking exon 27. Differential expression of CD133 splice variants was found in iris, ciliary body, retina, and retinal pigment epithelium/choroid as well as in uveal melanoma cell lines. mRNA for nestin, Sox2, and Musashi was present in all studied cell lines. Uveal melanoma such as cutaneous melanoma may therefore contain CSCs. Further experiments are needed to isolate stem cell marker-positive cells, to evaluate their functional properties and to explore therapeutical approaches to these putative CSCs in uveal melanoma.",
keywords = "Adult, Animals, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Immunohistochemistry, Mice, Antigens, CD/*biosynthesis/genetics, Glycoproteins/*biosynthesis/genetics, Intermediate Filament Proteins/biosynthesis, Melanoma/genetics/*metabolism/pathology, Neoplastic Stem Cells/*metabolism/pathology, Nerve Tissue Proteins/biosynthesis, Peptides/genetics, RNA, Messenger/biosynthesis/genetics, Tumor Markers, Biological/biosynthesis/genetics, Uveal Neoplasms/genetics/*metabolism/pathology, Adult, Animals, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Immunohistochemistry, Mice, Antigens, CD/*biosynthesis/genetics, Glycoproteins/*biosynthesis/genetics, Intermediate Filament Proteins/biosynthesis, Melanoma/genetics/*metabolism/pathology, Neoplastic Stem Cells/*metabolism/pathology, Nerve Tissue Proteins/biosynthesis, Peptides/genetics, RNA, Messenger/biosynthesis/genetics, Tumor Markers, Biological/biosynthesis/genetics, Uveal Neoplasms/genetics/*metabolism/pathology",
author = "Michelle Berna-Thill and Marc Berna and Rebecca Grierson and Inna Reinhart and Tobias Voelkel and Christoph Piechaczek and Peter Galambos and Jager, {Martine J} and Gisbert Richard and Claudia Lange and Ursula Gehling",
year = "2011",
language = "English",
volume = "21",
pages = "405--416",
journal = "MELANOMA RES",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

RIS

TY - JOUR

T1 - Expression of CD133 and other putative stem cell markers in uveal melanoma.

AU - Berna-Thill, Michelle

AU - Berna, Marc

AU - Grierson, Rebecca

AU - Reinhart, Inna

AU - Voelkel, Tobias

AU - Piechaczek, Christoph

AU - Galambos, Peter

AU - Jager, Martine J

AU - Richard, Gisbert

AU - Lange, Claudia

AU - Gehling, Ursula

PY - 2011

Y1 - 2011

N2 - 'Cancer stem cells' (CSCs) are tumor cells with stem cell properties hypothesized to be responsible for tumorigenesis, metastatis, and resistance to treatment, and have been identified in different tumors including cutaneous melanoma, using stem cell markers such as CD133. This study explored expression of CD133 and other putative stem cell markers in uveal melanoma. Eight uveal melanoma cell lines were subjected to flow-cytometric (fluorescence-activated cell sorting) analysis of CD133 and other stem cell markers. Eight paraffin-embedded tumors were analyzed by immunohistochemistry for CD133, Pax6, Musashi, nestin, Sox2, ABCB5, and CD68 expressions. Ocular, uveal melanoma, and hematopoietic stem cell distributions of C-terminal and N-terminal CD133 mRNA splice variants were compared by reverse-transcription PCR. Fluorescence-activated cell sorting analysis revealed a population of CD133-positive/nestin-positive cells in cell lines Mel270, OMM 2.3, and OMM2.5. All cell lines studied were positive for nestin, CXCR-4, CD44, and c-kit. Immunohistochemistry identified cells positive for CD133, Pax6, Musashi, nestin, Sox2, ABCB5, and CD68 predominantly at the invading tumor front. C-terminal primers interacting with CD133 splice variant s2 detected a novel variant lacking exon 27. Differential expression of CD133 splice variants was found in iris, ciliary body, retina, and retinal pigment epithelium/choroid as well as in uveal melanoma cell lines. mRNA for nestin, Sox2, and Musashi was present in all studied cell lines. Uveal melanoma such as cutaneous melanoma may therefore contain CSCs. Further experiments are needed to isolate stem cell marker-positive cells, to evaluate their functional properties and to explore therapeutical approaches to these putative CSCs in uveal melanoma.

AB - 'Cancer stem cells' (CSCs) are tumor cells with stem cell properties hypothesized to be responsible for tumorigenesis, metastatis, and resistance to treatment, and have been identified in different tumors including cutaneous melanoma, using stem cell markers such as CD133. This study explored expression of CD133 and other putative stem cell markers in uveal melanoma. Eight uveal melanoma cell lines were subjected to flow-cytometric (fluorescence-activated cell sorting) analysis of CD133 and other stem cell markers. Eight paraffin-embedded tumors were analyzed by immunohistochemistry for CD133, Pax6, Musashi, nestin, Sox2, ABCB5, and CD68 expressions. Ocular, uveal melanoma, and hematopoietic stem cell distributions of C-terminal and N-terminal CD133 mRNA splice variants were compared by reverse-transcription PCR. Fluorescence-activated cell sorting analysis revealed a population of CD133-positive/nestin-positive cells in cell lines Mel270, OMM 2.3, and OMM2.5. All cell lines studied were positive for nestin, CXCR-4, CD44, and c-kit. Immunohistochemistry identified cells positive for CD133, Pax6, Musashi, nestin, Sox2, ABCB5, and CD68 predominantly at the invading tumor front. C-terminal primers interacting with CD133 splice variant s2 detected a novel variant lacking exon 27. Differential expression of CD133 splice variants was found in iris, ciliary body, retina, and retinal pigment epithelium/choroid as well as in uveal melanoma cell lines. mRNA for nestin, Sox2, and Musashi was present in all studied cell lines. Uveal melanoma such as cutaneous melanoma may therefore contain CSCs. Further experiments are needed to isolate stem cell marker-positive cells, to evaluate their functional properties and to explore therapeutical approaches to these putative CSCs in uveal melanoma.

KW - Adult

KW - Animals

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Immunohistochemistry

KW - Mice

KW - Antigens, CD/biosynthesis/genetics

KW - Glycoproteins/biosynthesis/genetics

KW - Intermediate Filament Proteins/biosynthesis

KW - Melanoma/genetics/metabolism/pathology

KW - Neoplastic Stem Cells/metabolism/pathology

KW - Nerve Tissue Proteins/biosynthesis

KW - Peptides/genetics

KW - RNA, Messenger/biosynthesis/genetics

KW - Tumor Markers, Biological/biosynthesis/genetics

KW - Uveal Neoplasms/genetics/metabolism/pathology

KW - Adult

KW - Animals

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Immunohistochemistry

KW - Mice

KW - Antigens, CD/biosynthesis/genetics

KW - Glycoproteins/biosynthesis/genetics

KW - Intermediate Filament Proteins/biosynthesis

KW - Melanoma/genetics/metabolism/pathology

KW - Neoplastic Stem Cells/metabolism/pathology

KW - Nerve Tissue Proteins/biosynthesis

KW - Peptides/genetics

KW - RNA, Messenger/biosynthesis/genetics

KW - Tumor Markers, Biological/biosynthesis/genetics

KW - Uveal Neoplasms/genetics/metabolism/pathology

M3 - SCORING: Journal article

VL - 21

SP - 405

EP - 416

JO - MELANOMA RES

JF - MELANOMA RES

SN - 0960-8931

IS - 5

M1 - 5

ER -